You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
CNBC reports NIH Director Francis Collins told a congressional committee that assessing the safety and efficacy of COVID-19 vaccine is the agency's "top priority."
The company is currently working on multiple infectious disease products, including a panel for sexually transmitted infections and one for SARS-CoV-2.
The company's contract with the NIH offered $12 million total and after initial test verification, Fluidigm will receive approximately $11 million.
The grant, which was awarded under the NIH Pathway to Independence program, will fund research into the genetics of Alzheimer's disease.
The US National Institutes of Health is establishing the Centers for Research in Emerging Infectious Diseases to study pathogen spillover.
The Wall Street Journal reports EcoHealth Alliance can get its grant back if it provides information about the Wuhan Institute of Virology.
According to ScienceInsider, a US ethics board has rejected most of the applications it reviewed for using human fetal cells in research.
Funding from RADx and NIAID will enable the scale-up of multiplexed viral detection microarrays to 4 million tests per month.
The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.
The PCR diagnostic device is a palm-size, single-use, disposable device that detects N. gonorrhoeae and determines if it's susceptible to an antibiotic.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.